Based on the results of network pharmacology analysis, PIK3CA, EGFR, TP53, MAPK1, and MAPK3 were identified as key targets of FZP in HCC treatment, which was verified using western blotting. Here, MAPK3 is linked to hepatocellular carcinoma.